

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

Barb
[initials]

Access DB# 93045

SEARCH REQUEST FORM
Scientific and Technical Information Center

Requester's Full Name: Dwayne C. Jones Examiner #: 71299 Date: 02 MAY 03
Art Unit: 1611 Phone Number 30 8-4134 Serial Number: 101069179
Mail Box and Bldg/Room Location: 2004, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. me

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet
Inventors (please provide full names): 11

Earliest Priority Filing Date: 11

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search claims 3, 5 and 8

BEST AVAILABLE COPY

Point of Contact:
Barb O'Brien
Technical Information Specialist
STIC CM1 6A05 308-4291

REMOVED
[initials]

BEST AVAILABLE COPY

STAFF USE ONLY

Searcher: <u>BOB</u>	Type of Search: <u>NA</u>	Vendors and cost where applicable: <u>290</u>
Searcher Phone #: _____	NA Sequence (#) _____	STN _____
Searcher Location: _____	AA Sequence (#) _____	Dialog _____
Date Searcher Picked Up: _____	Structure (#) _____	Questel/Orbit _____
Date Completed: <u>5-9-03</u>	Bibliographic <u>8</u>	Dr.Link _____
Searcher Prep & Review Time: <u>30</u>	Litigation _____	Lexis/Nexis _____
Clerical Prep Time: _____	Fulltext _____	Sequence Systems _____
	Patent Family _____	WWW/Internet _____
	Other _____	Other (specify) _____

THIS PAGE BLANK (USPTO)

=> fil reg, e ifo/cn

FILE (REGISTRY) ENTERED AT 12:17:48 ON 09 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2003 HIGHEST RN 511677-22-8
DICTIONARY FILE UPDATES: 7 MAY 2003 HIGHEST RN 511677-22-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

E1	2	IFN-ALPHA RESPONSIVE TRANSCRIPTION FACTOR (HUMAN CELL LINE H ELA GENE ISGF3-GAMMA)/CN
E2	1	IFN-GAMMA-INDUCED (GTP-BINDING PROTEIN) PROTEIN MG11 RELATE D PROTEIN (THERMOPLASMA ACIDOPHILUM STRAIN DSM1728 GENE TA01 93)/CN
E3	0 -->	IFO/CN
E4	1	IFO 13140/CN
E5	1	IFOMIDE/CN
E6	1	IFOPOL/CN
E7	1	IFORRESTINE/CN
E8	1	IFOSFAMID/CN
E9	1	IFOSFAMIDE/CN
E10	1	IFOSFAMIDE MUSTARD/CN
E11	1	IFOSPHAMIDE/CN
E12	1	IFOSPHAMIDE 4-HYDROXYLASE/CN

=> fil capl

FILE=CAPLUS/ ENTERED AT 12:41:14 ON 09 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2003 VOL 138 ISS 20

FILE LAST UPDATED: 8 May 2003 (20030508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 128; d que 137; d que 138; d que 142

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR 117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR 189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR 63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/BI OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)

L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3

L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3

L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL

L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND L3

L28 4 SEA FILE=CAPLUS ABB=ON L4 OR L6 OR L7

L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN

L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN

L10 1 SEA FILE=REGISTRY ABB=ON CAROAZONE/CN

L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN

L32 16051 SEA FILE=CAPLUS ABB=ON OBESITY+NT/CT

L33 3505 SEA FILE=CAPLUS ABB=ON ANTI OBESITY AGENTS/CW

L36 10756 SEA FILE=CAPLUS ABB=ON (L8 OR L9 OR L10 OR L11)

L37 1 SEA FILE=CAPLUS ABB=ON L36 AND (L32 OR L33)

L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN

L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN

L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN

L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN

L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN

L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN

L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN


L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN

L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN

Circ41403 41803


Available	1	04/15/03	
Textbook of immunology; an introduction			30402002003764
QR181 .B3 c.1		BTECH	
Available	1	04/14/03	
Vaccine.			30402002091934
QR189 .V82 v.19		BTECH	
Available	1	04/16/03	
Vaccine.			30402002091645
QR189 .V82 v.20		BTECH	
Available	1	04/21/03	
The Oxford illustrated companion to			30402002699215
R121 .O884 2001 c.1		BTECH	
Available	1	04/18/03	
Medical guide to the mineral waters of			30402000721219
RA863.5 .V78 c.1		BTECH	
Checked out	1	04/18/03	
The Oxford medical companion /			30402000851255
RC41 .O84 1994 c.1		BTECH	
Available	1	04/16/03	
Cecil textbook of medicine /			30402001669623
RC46 .C423 21st ED		BT/REF	
Available	1	04/16/03	
Oncogene.			30402001296070
RC268.42 .O48 v.14		BTECH	
Checked out	1	04/21/03	
Hepatology : official journal of the			30402001260902
RC845 .H45 v.24		BTECH	
Available	1	04/17/03	
Journal of controlled release.			30402001795758
RS201.D4 J6 v.48-49		BTECH	
Available	1	04/14/03	
Journal of controlled release.			30402002053942
RS201.D4 J6 v.65		BTECH	
Available	1	04/14/03	
The Merck index : an encyclopedia of			30402001516766
RS356 .M524 2001 13th		BTECH	
Available	1	04/16/03	

①




L4

②



L7

③



L6

L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L31 1105 SEA FILE=CAPLUS ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L32 16051 SEA FILE=CAPLUS ABB=ON OBESITY+NT/CT
L33 3505 SEA FILE=CAPLUS ABB=ON ANTIOBESITY AGENTS/CW
L38 2 SEA FILE=CAPLUS ABB=ON L31 AND (L32 OR L33)

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR
117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18
-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR
189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/
BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR
63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/B
I OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)
L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3
L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3
L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL
L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND
L3
L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN
L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN
L10 1 SEA FILE=REGISTRY ABB=ON CAROXAZONE/CN
L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN
L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN
L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN
L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN
L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN
L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN
L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN
L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN
L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN
L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN
L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L28 4 SEA FILE=CAPLUS ABB=ON L4 OR L6 OR L7
L29 1 SEA FILE=REGISTRY ABB=ON "IFO 13140"/CN
L30 9303 SEA FILE=CAPLUS ABB=ON (L8 OR L9 OR L10) OR L29
L31 1105 SEA FILE=CAPLUS ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L32 16051 SEA FILE=CAPLUS ABB=ON OBESITY+NT/CT
L33 3505 SEA FILE=CAPLUS ABB=ON ANTIOBESITY AGENTS/CW
L34 1 SEA FILE=CAPLUS ABB=ON L28 AND (L32 OR L33)
L36 10756 SEA FILE=CAPLUS ABB=ON (L8 OR L9 OR L10 OR L11)
L37 1 SEA FILE=CAPLUS ABB=ON L36 AND (L32 OR L33)
L38 2 SEA FILE=CAPLUS ABB=ON L31 AND (L32 OR L33)
L39 14072 SEA FILE=CAPLUS ABB=ON BODY WEIGHT/CT
L40 15234 SEA FILE=CAPLUS ABB=ON APPETITE/CW
L41 22 SEA FILE=CAPLUS ABB=ON (L39 OR L40) AND (L31 OR L36 OR L30)
L42 21 SEA FILE=CAPLUS ABB=ON L41 NOT (L34 OR L37 OR L38),

=> s 128 or 137 or 138 or 142

L67 26 L28 OR L37 OR L38 OR L42

=> fil uspatf;d que 147; d que 143

FILE "USPATFULL" ENTERED AT 12:41:16 ON 09 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 8 May 2003 (20030508/PD)
FILE LAST UPDATED: 8 May 2003 (20030508/ED)
HIGHEST GRANTED PATENT NUMBER: US6560778
HIGHEST APPLICATION PUBLICATION NUMBER: US2003088899
CA INDEXING IS CURRENT THROUGH 8 May 2003 (20030508/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 8 May 2003 (20030508/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR
117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18
-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR
189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/
BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR
63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/B
I OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)
L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3
L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3
L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL
L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND
L3
L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN
L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN
L10 1 SEA FILE=REGISTRY ABB=ON CAROXAZONE/CN
L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN
L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN
L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN
L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN
L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN

L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN
L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN
L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN
L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN
L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN
L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L43 2 SEA FILE=USPATFULL ABB=ON L4 OR L6 OR L7
L44 336 SEA FILE=USPATFULL ABB=ON (L8 OR L9 OR L10 OR L11)
L45 91 SEA FILE=USPATFULL ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L46 2891 SEA FILE=USPATFULL ABB=ON OBESITY/CT OR (ANTIOBESITY AGENTS)/I
T OR BODY WEIGHT/CT OR APPETITE/IT
~~L47~~ 4 SEA FILE=USPATFULL ABB=ON L46 AND (L43 OR L44 OR L45)

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR
117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18
-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR
189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/
BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR
63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/B
I OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)
L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3
L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3
L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL
L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND
L3
~~L43~~ 2 SEA FILE=USPATFULL ABB=ON L4 OR L6 OR L7

=> s 147 or 143

~~L68~~ 6 L47 OR L43

=> fil medl; d que 148; d que 153

FILE 'MEDLINE' ENTERED AT 12:41:18 ON 09 MAY 2003

FILE LAST UPDATED: 8 MAY 2003 (20030508/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html>
for a description on changes.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR
117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18
-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR
189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/
BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR
63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/B

I OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)

L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3
L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3
L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL
L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND
L3
(L48 0 SEA FILE=MEDLINE ABB=ON L4 OR L6 OR L7 ;

L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN
L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN
L10 1 SEA FILE=REGISTRY ABB=ON CAROXAZONE/CN
L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN
L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN
L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN
L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN
L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN
L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN
L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN
L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN
L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN
L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN
L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L49 4183 SEA FILE=MEDLINE ABB=ON (L8 OR L9 OR L10 OR L11)
L50 785 SEA FILE=MEDLINE ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L51 51092 SEA FILE=MEDLINE ABB=ON OBESITY+NT/CT
L52 2988 SEA FILE=MEDLINE ABB=ON ANTI-OBESITY AGENTS/CT OR APPETITE
DEPRESSANTS/CT
(L53 2 SEA FILE=MEDLINE ABB=ON (L49 OR L50) AND (L51 OR L52))

=> fil embase, d que 154; d que 162; d que 166; s 162 or 166

(FILE 'EMBASE' ENTERED AT 12:41:20 ON 09 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 1 May 2003 (20030501/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L3 23 SEA FILE=REGISTRY ABB=ON (103878-84-8/BI OR 105365-76-2/BI OR
117854-28-1/BI OR 134564-82-2/BI OR 135204-83-0/BI OR 150366-18
-0/BI OR 176773-86-7/BI OR 18464-39-6/BI OR 185835-97-6/BI OR
189439-39-2/BI OR 189439-83-6/BI OR 205187-44-6/BI OR 262-20-4/
BI OR 29218-27-7/BI OR 54403-19-9/BI OR 60762-57-4/BI OR
63638-91-5/BI OR 71320-77-9/BI OR 76990-56-2/BI OR 77518-07-1/B
I OR 9001-66-5/BI OR 91406-11-0/BI OR 94011-82-2/BI)
L4 1 SEA FILE=REGISTRY ABB=ON QUINOLIN AND L3
L5 2 SEA FILE=REGISTRY ABB=ON CYCLOPROPYLMETHOXY AND L3
L6 1 SEA FILE=REGISTRY ABB=ON L5 AND BENZOFURANYL
L7 1 SEA FILE=REGISTRY ABB=ON TRIFLUOROBUTOXY AND BENZOFURANYL AND

L3
(L54) 0 SEA FILE=EMBASE ABB=ON L4 OR L6 OR L7

L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN
L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN
L10 1 SEA FILE=REGISTRY ABB=ON CAROXAZONE/CN
L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN
L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN
L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN
L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN
L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN
L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN
L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN
L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN
L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN
L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN
L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L55 12068 SEA FILE=EMBASE ABB=ON (L8 OR L9 OR L10 OR L11)
L56 2687 SEA FILE=EMBASE ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L57 46172 SEA FILE=EMBASE ABB=ON OBESITY+NT/CT
L61 2935 SEA FILE=EMBASE ABB=ON L57(L) (DT OR PC) /CT — DT = drug therapy
L62 6 SEA FILE=EMBASE ABB=ON (L55 OR L56) AND L61 PC = prevention & control

L8 2 SEA FILE=REGISTRY ABB=ON LAZABEMIDE?/CN
L9 2 SEA FILE=REGISTRY ABB=ON MILACEMIDE?/CN
L10 1 SEA FILE=REGISTRY ABB=ON CAROXAZONE/CN
L11 7 SEA FILE=REGISTRY ABB=ON IFO?/CN
L13 1 SEA FILE=REGISTRY ABB=ON BEFLOXATONE/CN
L14 2 SEA FILE=REGISTRY ABB=ON MOCLOBEMIDE?/CN
L15 2 SEA FILE=REGISTRY ABB=ON BROFAROMINE?/CN
L16 1 SEA FILE=REGISTRY ABB=ON PHENOXATHIIN/CN
L17 1 SEA FILE=REGISTRY ABB=ON ESUPRONE/CN
L18 1 SEA FILE=REGISTRY ABB=ON BEFOL/CN
L19 1 SEA FILE=REGISTRY ABB=ON "RS 8359"/CN
L20 1 SEA FILE=REGISTRY ABB=ON "T 794"/CN
L21 1 SEA FILE=REGISTRY ABB=ON "KP 9"/CN
L22 1 SEA FILE=REGISTRY ABB=ON "E 2011"/CN
L23 1 SEA FILE=REGISTRY ABB=ON TOLOXATONE/CN
L24 2 SEA FILE=REGISTRY ABB=ON PIRLINDOLE?/CN
L25 2 SEA FILE=REGISTRY ABB=ON AMIFLAMINE?/CN
L26 1 SEA FILE=REGISTRY ABB=ON SERCLOREMINE/CN
L27 1 SEA FILE=REGISTRY ABB=ON BAZINAPRINE/CN
L55 12068 SEA FILE=EMBASE ABB=ON (L8 OR L9 OR L10 OR L11)
L56 2687 SEA FILE=EMBASE ABB=ON (L13 OR L14 OR L15 OR L16 OR L17 OR
L18 OR L19 OR L20 OR L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR
L27)
L57 46172 SEA FILE=EMBASE ABB=ON OBESITY+NT/CT
L65 538 SEA FILE=EMBASE ABB=ON L57(L) SI/CT — SI = side effect
L66 11 SEA FILE=EMBASE ABB=ON L65 AND (L55 OR L56)

169 16-L62-OR L66

=> dup rem 153,167,169,168

FILE 'MEDLINE' ENTERED AT 12:41:41 ON 09 MAY 2003

FILE 'CAPLUS' ENTERED AT 12:41:41 ON 09 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:41:41 ON 09 MAY 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 12:41:41 ON 09 MAY 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L53

PROCESSING COMPLETED FOR L67

PROCESSING COMPLETED FOR L69

PROCESSING COMPLETED FOR L68

L70 50 DUP REM L53 L67 L69 L68 (0 DUPLICATES REMOVED)

ANSWERS '1-2' FROM FILE MEDLINE

ANSWERS '3-28' FROM FILE CAPLUS

ANSWERS '29-44' FROM FILE EMBASE

ANSWERS '45-50' FROM FILE USPATFULL

=> d'ibib ab hitrn 1-50; fil hom

L70 ANSWER 1 OF 50 MEDLINE

ACCESSION NUMBER: 2002448493 MEDLINE

DOCUMENT NUMBER: 22194873 PubMed ID: 12205440

TITLE: Lifestyle drug market booming.

COMMENT: Comment in: Nat Med. 2002 Dec;8(12):1336; author reply 1336

AUTHOR: Atkinson Tim

SOURCE: NATURE MEDICINE, (2002 Sep) 8 (9) 909.

Journal code: 9502015. ISSN: 1078-8956.

PUB. COUNTRY: United States

DOCUMENT TYPE: News Announcement

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200209

ENTRY DATE: Entered STN: 20020904

Last Updated on STN: 20030305

Entered Medline: 20020926

L70 ANSWER 2 OF 50 MEDLINE

ACCESSION NUMBER: 90090877 MEDLINE

DOCUMENT NUMBER: 90090877 PubMed ID: 2557169

TITLE: Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

AUTHOR: Lind M J; Margison J M; Cerny T; Thatcher N; Wilkinson P M

CORPORATE SOURCE: CRC Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, U.K.

SOURCE: CANCER CHEMOTHERAPY AND PHARMACOLOGY, (1989) 25 (2) 139-42.

Journal code: 7806519. ISSN: 0344-5704.

PUB. COUNTRY: GERMANY, WEST: Germany, Federal Republic of

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199001

ENTRY DATE: Entered STN: 19900328

Last Updated on STN: 19900328

Entered Medline: 19900129

AB The pharmacokinetics of intravenous ifosfamide were determined in 16

patients with carcinoma of the bronchus. In all 25% (4) of these patients were obese (i.e. greater than 20% over their ideal body weight). The terminal elimination half-life ($t_{1/2}$ beta) was found to be higher in the obese group than in the control group (6.36 h, range 5.77-7.45 h) vs 4.95 h, range 1.82-6.48 h) (P less than 0.05). This prolongation of the elimination half-life was due to an increased volume of distribution (Vd beta) in the obese group (42.81 l, range 35.49-51.90 l) vs 33.70 l range (17.76-50.62 l) (P less than 0.05). There was therefore no significant difference in total plasma clearance between the obese and normal groups. No correlation of ifosfamide plasma half-life was observed with total body weight (TBW) or ideal body weight (IBW). However, a significant positive correlation was observed between the percentage of IBW and plasma half-life. A strong positive correlation was observed between IBW and the plasma clearance of ifosfamide. The Vd beta correlated with both TBW and the percentage of IBW, but not with IBW itself. When Vd beta was normalised for IBW, there was a strong positive correlation with the percentage of IBW, suggesting that ifosfamide distribution into the TBW is higher than that into the IBW.

L70 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:651857 CAPLUS

DOCUMENT NUMBER: 137:195185

TITLE: Gemcitabine, ifosfamide and vinorelbine in advanced non-small cell lung cancer: a phase II study

AUTHOR(S): Recchia, Francesco; Lombardo, Marco; De Filippis, Sandro; Rosselli, Michele; Rea, Silvio

CORPORATE SOURCE: Unita operativa di Oncologia, Ospedale Civile di Avezzano, Universita degli studi di L'Aquila, Italy

SOURCE: Anticancer Research (2002), 22(2B), 1321-1328
CODEN: ANTRD4; ISSN: 0250-7005

PUBLISHER: International Institute of Anticancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: The objective of this phase II study was to det. the activity and toxicity of gemcitabine, ifosfamide and vinorelbine, in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naïve patients with unresectable, stage IIIB and stage IV NSCLC, measurable lesions and an Eastern Cooperative Oncol. Group (ECOG) performance status ≤ 3 , were entered into the trial. The treatment consisted of ifosfamide 1500 mg/m² on days 1 to 3 with vinorelbine 25 mg/m² and gemcitabine 1000 mg/m² on days 3 and 8, every 3 wk. Results: Fifty-four patients with stage IIIB (24%) and stage IV (76%) were enrolled into the trial. The median age of the patients was 65 yr. The performance status was 0-1, 2 and 3 in 48%, 43% and 9% of patients, resp. The histol. was mainly squamous cell carcinoma (52%), which was poorly-differentiated in 30% of patients. All patients, receiving a total of 249 chemotherapy courses, were assessable for response and toxicity on an intent-to-treat basis. Objective responses included complete response in 3 (5.6%) patients (95% CI: 1.1% to 15.3%), partial response in 26 (48.1%) patients (95% CI: 34.3% to 62.2%), giving an overall response rate of 53.7% (95% CI: 39.6% to 67.4%). Stable disease was obsd. in 20 (37%) patients (95% CI: 24.3% to 51.2%) and progressive disease in 5 (9.3%) patients (95% CI: 3% to 20.3%). The median time to progression was 8.8 mo (range: 2-55+ months). The median overall survival was 13.2 mo (range: 2-55+). The 1-yr survival rate was 56% for all patients, comprising 78% and 47% for stage IIIB and stage IV patients, resp. (p=0.088). Myelosuppression was the main side-effect with (WHO) grade 3/4 neutropenia and thrombocytopenia in 56% and 13% of the patients, resp. Conclusion: Our results showed that even patients with a poor performance status may benefit from gemcitabine, ifosfamide and vinorelbine treatment, with acceptable toxicity.

IT 3778-73-2, Ifosfamide

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gemcitabine, ifosfamide and vinorelbine in advanced non-small cell
lung carcinoma patients)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:724822 CAPLUS

DOCUMENT NUMBER: 138:34312

TITLE: Prevalence of Fetal Exposure to Environmental Toxins
as Determined by Meconium Analysis

AUTHOR(S): Ostrea, Enrique M.; Morales, Victor; Ngoumgna,
Etienne; Prescilla, Randy; Tan, Edwina; Hernandez,
Emilio; Ramirez, Gloria Baens; Cifra, Herminia L.;
Manlapaz, Maria Luisa

CORPORATE SOURCE: Department of Pediatrics, Wayne State University,
Hutzel Hospital, Detroit, MI, USA

SOURCE: Neurotoxicology (2002), 23(3), 329-339
CODEN: NRTXDN; ISSN: 0161-813X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The primary objective was to det. whether environmental pollutants,
specifically Pb, Cd, Hg, As, and organochlorine and organophosphate
pesticides can be detected in meconium. Infants were randomly recruited
from the nurseries of five hospitals in Manila, Philippines. Their stools
(meconium) were collected and analyzed for heavy metals by at. absorption
spectrophotometry and for pesticides by gas chromatog./mass spectrometry
(GCMS). A total of 426 infants were studied. The exposure rate (based on
meconium anal.) and the median concn. of the pollutants in the pos.
samples were as follows: Pb (26.5%; 35.77 .mu.g/mL), Cd (8.5%; 13.37
.mu.g/mL), Hg (83.9%; 3.17 ng/mL), chlordane (12.7%; 22.48 .mu.g/mL),
chlorpyrifos (11.0%; 8.26 .mu.g/mL), diazinon (34.3%; 12.96 .mu.g/mL), DDT
(26.5%; 12.56 .mu.g/mL), lindane (73.5%; 2.0 .mu.g/mL), malathion (53.0;
6.80 .mu.g/mL), parathion (32.0%; 2.30 .mu.g/mL) and pentachlorophenol
(16.1%; 90.00 .mu.g/mL). Some maternal and neonatal factors that were
significantly assocd. with the presence of environmental toxins in
meconium included multigravidity, multiparity, multiple gestation,
meconium stained fluid, smoking, gestational age, low birth wt. and infant
gender. Meconium anal. is a new and sensitive tool to detect fetal
exposure to environmental toxins and its clin. use awaits further
investigation.

IT 121-75-5, Malathion

RL: ANT (Analyte); POL (Pollutant); ANST (Analytical study); OCCU
(Occurrence)

(fetal exposure to heavy metals and pesticides detd. by meconium anal.)

REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:564823 CAPLUS

DOCUMENT NUMBER: 135:132455

TITLE: Composition for treatment of stress

INVENTOR(S): Wurtman, Judith J.; Wurtman, Richard J.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001054681 A2 20010802 WO 2001-US2854 20010129
WO 2001054681 C1 20020117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1253915 A1 20021106 EP 2001-905173 20010129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2000-492110 A2 20000127
WO 2001-US2854 W 20010129

AB A method of treating stress in a patient showing stress related symptoms is disclosed, where the method comprises administering to the patient an effective amt. of a serotonergic drug or prodrug. Specific examples of such drugs are described, and include, among others, tryptophan or 5-hydroxytryptophan, or their salts.

IT 63638-91-5, Brofaromine 71320-77-9, Moclobemide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compn. for treatment of stress using serotonergic drugs or prodrugs)

L70 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:564797 CAPLUS

DOCUMENT NUMBER: 135:117204

TITLE: Computer-based cognitive function testing for measuring pharmaceutical-related cognitive impairment
INVENTOR(S): Erlanger, David; Kaplan, Darin; Shchogolev, Vladislav; Theodoracopoulos, Alexis; Yee, Philip; Comrie, McDonald

PATENT ASSIGNEE(S): Panmedix Incorporated, USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054650	A2	20010802	WO 2001-US2187	20010123
W:	AU, CA, CH, CZ, IL, JP, KR, SG, US, US, US, US, US, US			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			

AU 2001029717 A5 20010807 AU 2001-29717 20010123

PRIORITY APPLN. INFO.:

US 2000-494476 A 20000131
WO 2001-US2187 W 20010123

AB The invention generally involves using a computer to show a patient taking a pharmaceutical product a series of cognitive dysfunction tests, receiving the patient's test responses, and analyzing the responses to assess cognitive dysfunction in the patient, whereby a conclusion can be obtained regarding whether symptoms of cognitive dysfunction probably exist or are absent in the patient, and the drug's likely causal effect on cognitive dysfunction. The invention enables the comparison of multiple test results over time.

IT 103878-84-8, Lazabemide

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(computer-based cognitive function testing for measuring
pharmaceutical-related cognitive impairment)

L70 ANSWER 7 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:137010 CAPLUS

DOCUMENT NUMBER: 134:198077

TITLE: Use of monoamine oxidase inhibitors for the
manufacture of drugs intended for the treatment of
obesity

INVENTOR(S): Rosenzweig, Pierre

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: PCT Int. Appl., 11 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012176	A2	20010222	WO 2000-EP7917	20000808
WO 2001012176	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1078632 A1 20010228 EP 1999-116026 19990816 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO BR 2000013282 A 20020423 BR 2000-13282 20000808 EP 1210080 A2 20020605 EP 2000-951508 20000808 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL JP 2003506485 T2 20030218 JP 2001-516522 20000808 NO 2002000770 A 20020416 NO 2002-770 20020215 EP 1999-116026 A 19990816 WO 2000-EP7917 W 20000808				

PRIORITY APPLN. INFO.:

AB The present invention relates to the use of reversible selective inhibitors of monoamine oxidase A (MAO-A), reversible selective inhibitors of monoamine oxidase B (MAO-B) or reversible mixed inhibitors of MAO-A and MAO-B in the manuf. of drugs intended for the treatment of obesity. In obese rats, a 5-wk chronic treatment with befloxatone induced a dose related redn. of body wt. gain. This effect was significant from the first week of treatment of treatment for the dose of 10 mg/kg/day. An oral formulation of befloxatone was prepd. by granulating befloxatone 2.5 mg, starch 5 mg, lactose monohydrate 83 mg, Povidone K29/32 5 mg, Crospovidone 4 mg, and Mg stearate 0.5% and filling the granules obtained into gelatin capsules.

IT 262-20-4, Phenoxathiin 18464-39-6, Caroxazone
 29218-27-7, Toloxatone 54403-19-9, Sercloramine
 60762-57-4, Pirlindole 63638-91-5, Brofaromine
 71320-77-9, Moclobemide 76990-56-2, Milacemide
 77518-07-1, Amiflamine 91406-11-0, Esuprone
 94011-82-2, Bazinaprime 103878-84-8, Lazabemide
 105365-76-2, RS 8359 117854-28-1, Befol
 134564-82-2, Befloxatone 135204-83-0, T 794
 150366-18-0, E 2011 176773-86-7 189439-39-2

189439-83-6 205187-44-6, KP 9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. of monoamine oxidase inhibitors for treatment of obesity)

L70 ANSWER 8 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:678223 CAPLUS

DOCUMENT NUMBER: 136:363691

TITLE: Reversal of stress-induced memory changes by moclobemide: the role of neurotransmitters
AUTHOR(S): Nowakowska, Elzbieta; Chodera, Alfons; Kus, Krzysztof; Nowak, Przemyslaw; Szkilnik, Ryszard
CORPORATE SOURCE: Department of Pharmacology, Karol Marcinkowski University of Medical Sciences, Poznan, PL 61-701, Pol.

SOURCE: Polish Journal of Pharmacology (2001), 53(3), 227-233
CODEN: PJPAE3; ISSN: 1230-6002

PUBLISHER: Polish Academy of Sciences, Institute of Pharmacology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Studies on animals have shown that chronic stress is able to evoke behavioral changes such as locomotor activity deficit, decreased sleep, reduced food and water consumption and impaired memory. Chronic stress produces changes in concns. of neurotransmitters, mainly in the hippocampus. The hippocampus is a vulnerable brain structure that is involved in learning and memory functions. In this study, we investigated the effects of chronic stress procedure and moclobemide in rats, and the influence of chronic stress on the levels of monoamines: noradrenaline (NE), dopamine (DA) and serotonin (5-HT) in the rat hippocampus [as well as their metabolites: dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA)]. It was found out that chronic 21-day stress caused worsening of memory: the well trained rats after stress procedure lost their ability to find food quickly. Because of many errors in finding the way, the time these animals needed was on av. 2.4-times longer than that of the control group. Single, as well as prolonged (21 days) treatment with moclobemide (10 mg/kg/day) counteracted the deficit of memory induced by chronic stress. In stressed animals, we obsd. an increase in DA, decrease in DOPAC, 5-HT and 5-HIAA and decrease in NE levels. Moclobemide modulated the changes in the levels of neurotransmitters in the hippocampus, decreasing their turnover. The results demonstrate that moclobemide improves memory impaired by stress. They suggest also that moclobemide has a modulatory effect on stress-induced neurotransmitter changes which may be of importance for the protective effect of the drug with regard to memory impairment.

IT 71320-77-9, Moclobemide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(reversal of stress-induced memory changes by moclobemide and role of neurotransmitters)

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:585426 CAPLUS

DOCUMENT NUMBER: 135:235876

TITLE: Pharmacokinetics of alizapride in children receiving chemotherapy for solid tumour

AUTHOR(S): Rey, Elisabeth; Stettler, Eric; D'athis, Philippe; Pons, Gerard

CORPORATE SOURCE: Pharmacologie Perinatale et Pediatrique, Hopital Saint-Vincent de Paul, Universite Rene Descartes Paris V, Fr.

SOURCE: Fundamental & Clinical Pharmacology (2001), 15(3),
217-220
CODEN: FCPHEZ; ISSN: 0767-3981
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The purpose of the present study was to det. the pharmacokinetics of
alizapride to optimize its use in children aged 1 mo to 15 yr old who were
receiving chemotherapy. Seventeen children were given a single 4 mg/kg
alizapride infusion prior to the administration of cytostatic drugs.
Blood and urine samples were collected within 10 h after onset of the
infusion. Kinetic parameters were calcd. and showed a decrease in plasma
clearance expressed per unit of body wt. with age. The current data
suggest that dosage expressed per unit of body wt. should be higher in
children than in adults and higher in infants than in children.
IT 3778-73-2, Ifosfamide
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetics of alizapride in children receiving chemotherapy for
solid tumors)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:553442 CAPLUS
DOCUMENT NUMBER: 133:168383
TITLE: Pharmaceutical compositions containing nicotine or a
ligand of nicotine receptors and a monamine oxidase
inhibitor and their use for treating tobacco
withdrawal symptoms
INVENTOR(S): Caille, Dominique; George, Pascal; Jegham, Samir;
~~Robineau, Pascale~~; Scatton, Bernard; Zivkovic,
Branimir
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045846	A1	20000810	WO 2000-FR193	20000128
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2788982	A1	20000804	FR 1999-1144	19990202
FR 2788982	B1	20020802		
EP 1150715	A1	20011107	EP 2000-901660	20000128
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002536342	T2	20021029	JP 2000-596965	20000128
PRIORITY APPLN. INFO.:			FR 1999-1144	A 19990202
			WO 2000-FR193	W 20000128
OTHER SOURCE(S):		MARPAT 133:168383		

AB The invention concerns novel pharmaceutical compns. contg. nicotine or a ligand of nicotine receptors and a monamine oxidase inhibitor designed for treating tobacco withdrawal symptoms. A bilayer tablet contained befloxtone 5, lactose 66, microcryst. cellulose 20, povidone 4, crospovidone 4, and magnesium stearate 1% in the first layer, and nicotine polacrylix 5, microcryst. cellulose 20 povidone 4, hydroxypropyl Me cellulose 25, magnesium stearate 1, and lactose q.s. 100% in the second layer.

IT 176773-86-7 189439-39-2 189439-83-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical compns. contg. nicotine or ligand of nicotine receptors and monamine oxidase inhibitor and their use for treating tobacco withdrawal symptoms)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:98295 CAPLUS

DOCUMENT NUMBER: 132:141977

TITLE: Compositions containing moclobemide for treatment of pain

INVENTOR(S): Klein, Donald F.; Lederman, Seth

PATENT ASSIGNEE(S): Janus Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl. 73 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006138	A2	20000210	WO 1999-US17274	19990730
WO 2000006138	A3	20001116		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2338327	AA	20000210	CA 1999-2338327	19990730
CA 2338330	AA	20000210	CA 1999-2338330	19990730
WO 2000006140	A2	20000210	WO 1999-US17417	19990730
WO 2000006140	A3	20000518		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9952438	A1	20000221	AU 1999-52438	19990730
AU 9953305	A1	20000221	AU 1999-53305	19990730
JP 2002521431	T2	20020716	JP 2000-561993	19990730
JP 2002521433	T2	20020716	JP 2000-561995	19990730
US 2002032197	A1	20020314	US 2001-772679	20010130

PRIORITY APPLN. INFO.:

US 1998-94934P P 19980731
US 1998-94984P P 19980731
US 1998-94985P P 19980731
US 1998-94987P P 19980731
US 1998-94989P P 19980731
WO 1999-US17274 W 19990730
WO 1999-US17417 W 19990730

AB The invention relates to methods and comps. for treating, managing, and/or preventing certain pain and pain disorders post-traumatic stress disorder, premenstrual dysphoric disorder and premenstrual syndrome, certain sleep and eating disorders, and symptoms by using moclobemide, a moclobemide metabolite, a moclobemide deriv. or a moclobemide compn. Gelatin capsules were prepd. from moclobemide 50.0, lactose 124.5, corn starch 25.0, Mg stearate and 0.5 mg/capsule.

IT **64544-22-5**, Moclobemide hydrochloride **71320-77-9**,
Moclobemide **71320-77-9D**, Moclobemide, derivs. or metabolites
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comps. contg. moclobemide for treatment of pain)

L70 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:68328 CAPLUS

DOCUMENT NUMBER: 132:117552

TITLE: Composition and method using serotonergic drug for treatment of stress

INVENTOR(S): Wurtman, Judith J.; Wurtman, Richard J.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003701	A1	20000127	WO 1999-US16153	19990716
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2337507	AA	20000127	CA 1999-2337507	19990716
EP 1096927	A1	20010509	EP 1999-934107	19990716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002520353	T2	20020709	JP 2000-559836	19990716

PRIORITY APPLN. INFO.:

US 1998-93013P P 19980716
WO 1999-US16153 W 19990716

AB A method of treating stress in a patient showing stress-related symptoms comprises administering to the patient an effective amt. of a serotonergic drug. Specific examples of this class of drugs are described, and include as examples, among others, the use of lithium, chlorimipramine, fluoxetine, fluvoxamine, sertraline, MK-212, Ro 60-0332/ORG 35035, Ro 60-175/ORG 35030, d,l-fenfluramine, dexfenfluramine, or a salt thereof.

IT **63638-91-5**, Brofaromine **71320-77-9**, Moclobemide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(serotonergic drug for treatment of stress)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:741882 CAPLUS

DOCUMENT NUMBER: 132:216932
TITLE: Toxicological response of rats to a novel monoamine oxidase type-a inhibitor, (5R)-3-[2-((1S)-3-cyano-1-hydroxypropyl)benzothiazol-6-yl]-5-methoxymethyl-2-oxazolidinone (E2011), orally administered for 13 weeks
AUTHOR(S): Sato, Gen; Chimoto, Tadashi; Aoki, Toyohiko; Hosokawa, Satoru; Sumigama, Shuji; Tsukidate, Kazuo; Sagami, Fumio
CORPORATE SOURCE: Drug Safety & Disposition Research Laboratories, Eisai Co., Ltd., Tokoclai, Tsukuba-shi, Ibaraki, 300-2635, Japan
SOURCE: Journal of Toxicological Sciences (1999), 24(3), 165-175
CODEN: JTSCDR; ISSN: 0388-1350
PUBLISHER: Japanese Society of Toxicology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB (5R)-3-[2-((1S)-3-cyano-1-hydroxypropyl)benzothiazol-6-yl]-5-methoxymethyl-2-oxazolidinone (E2011) is a novel monoamine oxidase type-A (MAO-A) inhibitor. In order to assess toxicol. profiles of E2011, doses of 0 (as controls), 30, 100 mg/kg of E2011 were administered to male and female Sprague-Dawley rats once a day for 13 wk orally by gavage. No mortality or any toxic signs except salivation occurred due to E2011 treatment. Decreased body wt. gain and food consumption, increases of alk. phosphatase and increases of liver wt. were the major treatment-related findings obsd. predominantly in the 100 mg/kg group. Histol. examn. revealed nuclear enlargement of hepatocytes with appearance of altered cell foci in some cases, and acinar atrophy in Harderian glands in the 100 mg/kg group. Since the histopathol. findings in the liver were indicative of an ongoing carcinogenic process, glutathione S-transferase placental form (GST-P) pos. hepatic foci were identified immunohistochem. and examd. morphometrically. Although GST-P pos. hepatic foci were detected in all groups including controls, the no. and area of GST-P pos. hepatic foci were significantly higher in female rats treated with 100 mg/kg than those in controls. In this paper, possible mechanisms of specific lesions in the liver and Harderian glands will be discussed.
IT 150366-18-0, E2011
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(E2011, monoamine oxidase type-a inhibitor, toxicol.)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L70 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:354011 CAPLUS

DOCUMENT NUMBER: 126:330609

TITLE: Preparation of oxazolidin-2-one derivatives as monoamine oxidase inhibitors

INVENTOR(S): Jegham, Samir; Puech, Frederic; Burnier, Philippe; Berthon, Danielle; Leclerc, Odile

PATENT ASSIGNEE(S): Synthelabo S. A., Fr.; Jegham, Samir; Puech, Frederic; Burnier, Philippe; Berthon, Danielle; Leclerc, Odile

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 9713768 A1 19970417 WO 1996-FR1511 19961008
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG
FR 2739856 A1 19970418 FR 1995-11902 19951011
FR 2739856 B1 19971114
FR 2751651 A1 19980130 FR 1996-9361 19960725
FR 2751651 B1 19980904
FR 2751653 A1 19980130 FR 1996-9362 19960725
FR 2751653 B1 19980904
AU 9671359 A1 19970430 AU 1996-71359 19961008
EP 891358 A1 19990120 EP 1996-932663 19961008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI
JP 11513400 T2 19991116 JP 1996-514756 19961008
ZA 9608568 A 19970513 ZA 1996-8568 19961010
US 5969146 A 19991019 US 1998-51539 19980413
PRIORITY APPLN. INFO.: FR 1995-11902 A 19951011
FR 1996-9361 A 19960725
FR 1996-9362 A 19960725
WO 1996-FR1511 W 19961008

OTHER SOURCE(S): MARPAT 126:330609

AB Oxazolidin-2-ones I [R1 = H, alkyl, hydroxyalkyl, fluoroalkyl, hydroxyfluoroalkyl, cyanoalkyl, optionally substituted Ph, optionally substituted phenylmethyl, cyclooxyalkyl optionally substituted by a hydroxy group; R2 = H, Me; X = O, S, NR3; R3 = H, alkyl; Z = O, CH=CH, CH2CH2] were prepd. and have Ki as inhibitors of monoamine oxidase A and B 1.2->1000 nM and 0.3->1000 Nm. Thus, (R)-4-methoxymethyl-1,3-dioxolan-2-one (II) was prepd. from (R)-2,2-dimethyl-1,3-dioxolane-4-methanol by methylation, ketal hydrolysis, and reaction with (EtO)2CO. Et 6-benzyloxybenzofuran-3-ylcarbamate was prepd. fom 2,4-HO(PhCH2O)C6H3CHO in 6 steps and was treated with II to give I [R1 = CH2Ph, R2 = Me, X = Z = O].

IT 189439-39-2P 189439-83-6P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazolidinone derivs. as monoamine oxidase inhibitors)

L70 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:303735 CAPLUS

DOCUMENT NUMBER: 124:343284

TITLE: Preparation of oxazoloquinolinones as monoamine oxidase inhibitors

INVENTOR(S): Jegham, Samir; Koenig, Jean Jacques; Puech, Frederic; Burnier, Philippe; Zard, Lydia

PATENT ASSIGNEE(S): Synthelabo S. A., Fr.

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 699680	A1	19960306	EP.1995-401989	19950901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2724171	A1	19960308	FR 1994-10600	19940905
FR 2724171	B1	19970103		
US 5641785	A	19970624	US 1995-523508	19950901

AT 190311	E	20000315	AT 1995-401989	19950901
ES 2145886	T3	20000716	ES 1995-401989	19950901
FI 9504141	A	19960306	FI 1995-4141	19950904
NO 9503458	A	19960306	NO 1995-3458	19950904
AU 9530415	A1	19960321	AU 1995-30415	19950904
AU 687591	B2	19980226		
ZA 9507414	A	19960415	ZA 1995-7414	19950904
JP 08099881	A2	19960416	JP 1995-226462	19950904
HU 73435	A2	19960729	HU 1995-2578	19950904
HU 218587	B	20001028		
CN 1128763	A	19960814	CN 1995-117143	19950904
CN 1055472	B	20000816		
RU 2141482	C1	19991120	RU 1995-114741	19950904
CZ 286128	B6	20000112	CZ 1995-2262	19950904
SK 281867	B6	20010806	SK 1995-1089	19950904
PL 184412	B1	20021031	PL 1995-310273	19950904
IL 115276	A1	19981206	IL 1995-115276	19950912
HK 1013652	A1	20010119	HK 1998-114972	19981223

PRIORITY APPLN. INFO.: FR 1994-10600 A 19940905

OTHER SOURCE(S): MARPAT 124:343284

AB Title compds. [I; R = R4R3R2CCHR5(CH2)n; R1 = H, CH:CH2, Me, Et, Ph, CH2OH, CH2OMe; R2 = Me, CF3, or cyano, R3 = H, OH, or OCH2Ph, and R4 = R5 = H; R2R4 = (CH2)4, R3 = OH, and R5 = H; R2R5 = O(CH2)3, R3 = H or OH, and R4 = H; n = 0 or 1] were prepd. Thus, Et 2-formyl-6-methoxy-1,2,3,4-tetrahydroquinoline-1-carboxylate was condensed with CH2:CHMgBr and the O-demethylated trans-product etherified with (R)-1-iodo-3-hydroxy-4,4,4-trifluorobutane to give title compd. II. I had ED50 of 0.2-1.1mg/kg orally for potentiation of L-5-hydroxytryptophan-induced tremors in rats.

IT 176773-86-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of oxazoloquinolinones as monoamine oxidase inhibitors)

L70 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:23419 CAPLUS

DOCUMENT NUMBER: 120:23419

TITLE: Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa

AUTHOR(S): Kennedy, Sidney H.; Davis, Bruce A.; Brown, Gregory M.; Ford, Christine G.; d'Souza, Joseph

CORPORATE SOURCE: Dep. Psychiatry, Univ. Toronto, Toronto, ON, Can.

SOURCE: Neurochemical Research (1993), 18(12), 1281-5

CODEN: NEREDZ; ISSN: 0364-3190

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Brofaromine, a selective and reversible inhibitor of monoamine oxidase-A (MAO-A) was given to 19 women while 17 received placebo for 8 wk. All met DSM III-R criteria for bulimia nervosa, a psychiatric disorder in which uncontrolled overeating episodes are accompanied by purging activities and extreme concerns about body shape and wt. The following indexes were measured: plasma and urinary phenylacetic acid (PAA), homovanillic acid (HVA), vanillylmandelic acid (VMA); plasma tryptamine (T), .beta.-phenylethylamine (PE), and 5-hydroxyindoleacetic acid (5-HIAA) and urinary 6-sulfatoxymelatonin (aMT6s). PE levels remained the same but T showed a trend toward elevation over time. Twenty-four hour levels of urinary aMT6s in BN patients were higher at week 4 when compared to baseline and week 8. There was a significant redn. in plasma VMA and HVA over time during treatment with brofaromine and both plasma HVA and VMA were significantly lower for the brofaromine group compared to placebo at week 4. Plasma 5-HIAA was significantly higher for the brofaromine group after 8 wk when compared to placebo. Urinary VMA decreased significantly

from baseline to week 4 with a partial elevation at 8 wk. Urinary VMA was also significantly lower in patients on brofaromine at week 4. This study verifies that brofaromine complies with predicted MAO-A inhibiting patterns in a clin. population.

IT 63638-91-5, Brofaromine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(acid metabolites and biogenic amines response to, in human bulimia nervosa, monoamine oxidase A inhibition in relation to)

L70 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:729 CAPLUS

DOCUMENT NUMBER: 116:729

TITLE: Serotonergic drugs for treatment of appetite and mood disturbances associated with the premenstrual syndrome

INVENTOR(S): Wurtman, Richard J.; Wurtman, Judith J.

PATENT ASSIGNEE(S): USA

SOURCE: Can. Pat. Appl., 29 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2002182	AA	19910503	CA 1989-2002182	19891103
PRIORITY APPLN. INFO.:			CA 1989-2002182	19891103

AB Serotonergic drugs, such as d-fenfluramine and fluoxetine are used for the treatment of mood and/or appetite disturbances assocd. with the premenstrual syndrome. Administration of 30 mg d-fenfluramine/day, for 15 day prior to the expected menstrual period decreased depression and other neg. mood states, as detd by the Hamilton depression scale.

IT 63638-91-5, Brofaromine 71320-77-9, Moclobemide

RL: BIOL (Biological study)

(appetite and mood disturbances treatment by, in premenstrual syndrome)

L70 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:619 CAPLUS

DOCUMENT NUMBER: 116:619

TITLE: Light-dark phase differences in behavioral effects of moclobemide in rats

AUTHOR(S): Gorka, Zbigniew; Zajaczkowski, Wojciech

CORPORATE SOURCE: Inst. Pharmacol., Pol. Acad. Sci., Krakow, 31-343, Pol.

SOURCE: Polish Journal of Pharmacology and Pharmacy (1991), 43(3), 177-86.

CODEN: PJPPAA; ISSN: 0301-0244

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of single and repeated administration of the MAO-A inhibitor moclobemide (MOC) on the spontaneous locomotor activity and motor hyper- and hypoactivity induced by d-amphetamine and clonidine, resp., in male rats were studied in the light (L) and dark (D) phases of the diurnal cycle. In the light phase, 2 h after single administration, MOC (10 and 50 mg/kg orally) increased the basal activity and a dose of 50 mg/kg decreased the exploratory and gross activities and enhanced the effects of amphetamine and clonidine. In the dark phase, MOC (50 mg/kg) increased the gross activity and potentiated the amphetamine hyperactivity. Only exploration was diminished to the same extent as in the light phase. After repeated administration, MOC increased only the gross activity in the light phase. In the dark phase, MOC diminished the exploration and

potentiated the amphetamine hyperactivity. MOC, in both doses used, diminished food and water consumption and the body wt. gain during the treatment period. MOC influences the behavior of rats in a phase-dependent manner after single and repeated administration.

IT 71320-77-9, Moclobemide

RL: BIOL (Biological study)

(motor and exploratory behavior response to, diurnal rhythm differences in)

L70 ANSWER 19 OF 50 CARLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:75234 CAPLUS

DOCUMENT NUMBER: 114:75234

TITLE: Serotonergic drugs for treating tobacco withdrawal symptoms

INVENTOR(S): Wurtman, Richard J.; Wurtman, Judith J.; Spring, Bonnie

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 28 pp..

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9004387	A2	19900503	WO 1989-US4743	19891025
WO 9004387	A3	19900628		
W: JP				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4999382	A	19910312	US 1988-262625	19881026
EP 440704	A1	19910814	EP 1989-912045	19891025
EP 440704	B1	19951011		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 04501413	T2	19920312	JP 1989-511314	19891025
JP 2997280	B2	20000111		
AT 128864	E	19951015	AT 1989-912045	19891025
CA 2001572	AA	19900426	CA 1989-2001572	19891026
CA 2001572	C	20010102		
US 5179126	A	19930112	US 1990-619301	19901128

PRIORITY APPLN. INFO.:

US 1988-262625 A 19881026

WO 1989-US4743 W 19891025

AB Disturbances of mood and appetite assocd. with nicotine withdrawal are treated by administering an effective quantity of a drug which selectively enhances serotonin-mediated neurotransmission. Subjects in a smoking withdrawal treatment program were given 2.15 mg d-fenfluramine (I) doses daily or placebo. The receiving the placebo gained, on av. 3.42 lbs; those receiving I lost, on av. 2.0 lbs. Of subjects on I, 62% were able to remain off cigarettes during the 29-day test period; only 39% of the placebo group succeeded in doing so.

IT 63638-91-5 71320-77-9, Moclobemide

RL: BIOL (Biological study)

(tobacco withdrawal symptoms treatment with)

L70 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:134491 CAPLUS

DOCUMENT NUMBER: 112:134491

TITLE: Therapeutic action of acetylcholine in malathion toxicity

AUTHOR(S): Pant, Radha; Ramana, D.

CORPORATE SOURCE: Chem. Dep., Allahabad Agric. Inst., Allahabad, 211007, India

SOURCE: Indian Journal of Biochemistry & Biophysics (1989),

26(4), 268-72

CODEN: IJBBBQ; ISSN: 0301-1208

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The administration of malathion to the developing *Philosamia ricini* larvae induces accumulation of acetylcholine, marked inhibition of acetylcholinesterase activity, depletion of all nutrients, heavy wt. loss, and high mortality. Pretreatment of the larvae with acetylcholine via feed reduces malathion toxicity and conversely, feeding of acetylcholine to malathion-treated larvae reverses the toxic effects. Resumption of normal control feed to malathion-treated insects results in higher mortality than in insects fed acetylcholine after exposure to malathion. This emphasizes the therapeutic action of acetylcholine. Feeding of a mixt. of equal quantities of malathion and acetylcholine recorded significantly lower mortality among insects in comparison to those fed malathion alone. This further supports the protective action of acetylcholine. Reversal of malathion toxicity and the protective action of acetylcholine have been attributed to the mediation of choline, an essential insect vitamin that gets released as a catabolic product of acetylcholine.

IT 121-75-5, Malathion

RL: PRP (Properties)

(toxicity of, to *Philosamia ricini* during larval development,
acetylcholine protection against)

L70 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:450320 CAPLUS

DOCUMENT NUMBER: 111:50320

TITLE: Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors

AUTHOR(S): Fletcher, P. J.; Yu, P. H.

CORPORATE SOURCE: Neuropsychiatr. Res. Unit, Univ. Saskatchewan,
Saskatoon, SK, S7N 0W0, Can.SOURCE: Psychopharmacology (Berlin, Germany) (1989), 98(2),
265-8

CODEN: PSCHDL; ISSN: 0033-3158

DOCUMENT TYPE: Journal

LANGUAGE: English

AB S.c. injection of 1 mg 5-hydroxytryptamine (5-HT)/kg reduced the intake of a 10% sucrose soln. in rats. A single injection of the monoamine oxidase inhibitor (MAOI) clorgyline enhanced the anorectic effect of 5-HT. This effect persisted 2, 24, 48, 72, and 96 h after injection. The clorgyline treatment almost completely inhibited type A MAO activity in the liver at 2 h post-injection. By 120 h the potentiation of 5-HT induced anorexia disappeared and MAO-A activity returned to 80% of control values. Thus, the clorgyline effect is long-lasting and irreversible. Brofaromine (5 mg/kg) and cimoxatone (20 mg/kg) also enhanced the anorectic effect of 5-HT injected 2 h later. The potentiating effects of brofaromine and cimoxatone were not obsd. when 5-HT was administered 24 h later. Apparently, brofaromine and cimoxatone are short-acting, reversible inhibitors of MAO-A activity in vivo. Moclobemide (30 mg/kg) failed to enhance the anorectic action of 5-HT injected 2 and 24 h later. The potentiation of 5-HT-induced anorexia may be a useful behavioral test for investigating the degree of reversibility and time course of MAOis actions.

IT 63638-91-5, Brofaromine

RL: BIOL (Biological study)

(anorexia from serotonin enhancement by, reversibility of)

IT 71320-77-9, Moclobemide

RL: BIOL (Biological study)

(anorexia from serotonin response to, reversibility of)

L70 ANSWER 22 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:130147 CAPLUS
DOCUMENT NUMBER: 110:130147
TITLE: Development of addiction to carbophos in the offspring of rats during administration in pregnancy
AUTHOR(S): Ivashin, V. M.; Bandazhevskii, Yu. I.; Oboznyi, N. D.; Zakharichenko, R. G.
CORPORATE SOURCE: Med. Inst., Grodino, USSR
SOURCE: Farmakologiya i Toksikologiya (Moscow) (1989), 52(1), 87-90
CODEN: FATOAO; ISSN: 0014-8318
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB In 2-mo-old rats exposed in vitro (days 11, 13, 15, and 17 of pregnancy) to carbophos (10 mg/kg, intragastrically to pregnant dams), 66.7% of females and 46.2% of males developed addiction to carbophos. Similar but smaller preference was obsd. in offsprings of rats treated with 5 or 100 mg carbophos/kg. Body wt. of newborns of dams treated with 5 or 10 mg carbophos/kg were below controls.
IT 121-75-5, Carbophos
RL: BIOL (Biological study)
(dependence on, in newborn, embryotoxicity and behavioral teratogenicity in relation to)

L70 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:149514 CAPLUS
DOCUMENT NUMBER: 110:149514
TITLE: Long-term effects of pesticides endosulfan, malathion and sevin on the fish *Puntius stigma*
AUTHOR(S): Khillare, Y. K.; Wagh, S. B.
CORPORATE SOURCE: Dep. Zool., Marathwada Univ., Aurangabad, 431004, India
SOURCE: Environment and Ecology (1988), 6(3), 589-93
CODEN: ENECEV; ISSN: 0970-0420
DOCUMENT TYPE: Journal
LANGUAGE: English
AB P. stigma showed changes in survival, feeding, growth rate, and oxygen consumption during chronic exposure to endosulfan, malathion, and sevin. Endosulfan induced the highest (10-40%) and sevin the lowest (10%) mortality. Growth rate was reduced after exposure for 16 wk. Depletion in the oxygen consumption in fish was also found.
IT 121-75-5, Malathion
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity of, to *Puntius stigma*)

L70 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1988:487780 CAPLUS
DOCUMENT NUMBER: 109:87780
TITLE: Toxicological effects of dietary malathion in cockerels
AUTHOR(S): Varshneya, C.; Bahga, H. S.; Sharma, L. D.
CORPORATE SOURCE: Govind Ballabh Pant Univ. Agric. Technol., Uttar Pradesh, 263 145, India
SOURCE: Indian Journal of Animal Sciences (1988), 98(4), 411-14
CODEN: IJLAA4; ISSN: 0367-8318
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Cockerels were fed a ration contg. 0, 400, 800, and 1600 ppm malathion for 90 days to study biochem. changes in serum and histopathol. changes in liver, spleen, adrenals, and thyroids. Cockerels receiving the insecticide at 800 and 1600 ppm showed a significant increase in serum aspartate aminotransferase activity. Malathion at dietary levels of 400, 800, and 1600 ppm caused significant inhibition in serum cholinesterase

activity. Total lipids were significantly increased only at 1600 ppm, whereas total serum cholesterol levels were significantly higher at 400, 800, and 1600 ppm. Serum levels of total proteins, bilirubin, and protein-bound I, however, remained unaltered. Livers from insecticide-treated birds showed varying degrees of hydropic degeneration and hepatocellular necrosis. Lymphoid follicles of the spleen showed necrotic as well as hyperplastic changes. Degenerative changes were also obsd. in the adrenal cortex. The thyroids, however, did not exhibit any change in their morphol.

IT 121-75-5, Malathion

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity of, in cockerels, dosage in relation to)

L70 ANSWER 25 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1988:181850 CAPLUS

DOCUMENT NUMBER: 108:181850

TITLE: Impact of Metacide and Cythion on food utilization, growth and conversion efficiency of a fish Macropodus cupanus

AUTHOR(S): Muniandy, S.

CORPORATE SOURCE: Post Grad. Res. Dep. Zool., APA Coll. Arts Culture, Palani, 624602, India

SOURCE: Environment and Ecology (1987), 5(4) 766-8

CODEN: ENECEV; ISSN: 0970-0420

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Feeding, growth, and conversion efficiency in M. cupanus were decreased with increasing concn. of Metacide and Cythion. The conversion efficiency of fish reared in different sublethal concns. of Metacide and Cythion decreased gradually. Slight difference was found in the feeding rate of the fish reared in Metacide and Cythion. The growth and conversion efficiency of the fish in Metacide seemed to be less than that reared in Cythion.

IT 121-75-5, Cythion

RL: BIOL (Biological study)

(Macropodus cupanus conversion efficiency and food utilization and growth response to)

L70 ANSWER 26 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:592530 CAPLUS

DOCUMENT NUMBER: 107:192530

TITLE: The relationship of life history attributes to toxicant tolerance in fishes

AUTHOR(S): Neuhold, John M.

CORPORATE SOURCE: Coll. Nat. Resour., Utah State Univ., Logan, UT, 84322-5200, USA

SOURCE: Environmental Toxicology and Chemistry (1987), 6(9), 709-16

CODEN: ETOCDK; ISSN: 0730-7268

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relation between tolerance to toxicants and fish species longevity, max. wt. attained, and fecundity is demonstrated. Among species, longevity and max. wt. attained is neg. related to tolerance to toxicants, while fecundity is pos. related to toxicant tolerance. The mode of action of toxicants is related to longevity and fecundity among species.

IT 121-75-5, Malathion

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity of, tolerance to, in fish, life history attributes in relation to)

L70 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1984:208006 CAPLUS

DOCUMENT NUMBER: 100:208006
TITLE: Effects of dichlorvos, maldison and pirimiphos-methyl on ~~feed consumption, egg~~ production, egg and tissue residues, and plasma acetylcholinesterase inhibition in layer strain hens
AUTHOR(S): Pym, R. A. E.; Singh, G.; Gilbert, W. S.; Armstrong, J. P.; McCleary, B. V.
CORPORATE SOURCE: Poul. Res. Stn., Dep. Agric., Seven Hills, 2147, Australia
SOURCE: Australian Journal of Experimental Agriculture and Animal Husbandry (1984), 124, 83-92
CODEN: AAAHAN; ISSN: 0045-060X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In 3 expts. laying performance was studied in hens given graded levels of maldison [11096-67-6], dichlorvos [62-73-7], and pirimiphos-methyl [29232-93-7] either sep. or combined in the feed over a 4-wk test period. There was interaction between dichlorvos and maldison as measured by depressed feed consumption and egg prodn. Combining the 3 insecticides, at levels which when given sep. had no effect, severely depressed feed consumption and egg prodn. After 4 wks on treatment, birds receiving pirimiphos-Me at 50 .mu.g/g of diet had residues of 0.08-0.17 .mu.g/g in fat and 0-0.06 .mu.g/g in muscle, and residues of 0-0.07 .mu.g/g maldison were recovered in the fat of birds receiving it at 100 .mu.g/kg of diet. No residues of any insecticide were detected in eggs and no dichlorvos residues were detected in any tissues. Plasma acetylcholinesterase (AChE) [9000-81-1], levels were reduced by 70% with dichlorvos at 30 .mu.g/g, by 30% with maldison at 10 .mu.g/g, and by 90% with pirimiphos-Me at 50 .mu.g/g. There was no indication of potentiation between insecticides as measured by plasma AChE inhibition, and effects upon feed consumption and egg prodn. appeared unrelated to plasma AChE activity. The relationship between feed consumption and egg prodn. was similar in groups receiving dichlorvos-maldison mixts. and in those receiving graded levels of untreated feed, indicating that the insecticides effect upon egg prodn. was mediated via a reduced feed intake. Max. residue limits for pesticides in feeds should be based on a total index which takes account of interaction between the different pesticides present.

IT 11096-67-6
RL: BIOL (Biological study)
(appetite and egg prodn. and plasma acetylcholinesterase of hens response to dietary)

L70 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1981:509852 CAPLUS
DOCUMENT NUMBER: 95:109852
TITLE: Toxicity of malathion to a freshwater fish, Channa punctatus. I. Median tolerance limit (TLM) measurements for malathion (organophosphate) to a freshwater fish, Channa punctatus.
AUTHOR(S): Chaturvedi, L. D.; Saxena, V. P.
CORPORATE SOURCE: Dep. Zool., Hindu Coll., Moradabad, India
SOURCE: Agra University Journal of Research, Science (1980), Volume Date 1979, 28(1), 159-67
CODEN: AURSA9; ISSN: 0002-1032
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The TLM values (concns. at which 50% of the test animals survive after a specific exposure period) of malathion [121-75-5] for C. punctatus was 8.6-10.2 ppm after 6-96 h. Temp., pH, DO, and fish size changes showed significant effects on the sensitivity of the freshwater fish to malathion.

IT 121-75-5

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity of, to Channa punctatus)

L70 ANSWER 29 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2002197838 EMBASE

TITLE: The impact of fatty acid oxidation on energy utilization:
Targets and therapy.

AUTHOR: Bebernitz G.R.; Schuster H.F.

CORPORATE SOURCE: G.R. Bebernitz, Novartis Pharmaceuticals Corporation,
Novartis Institute for Biomed. Res.,
Metabolic/Cardiovascular Dis. Dept., 556 Morris Avenue,
Summit, NJ 07901, United States.
greg.Bebernitz@pharma.novartis.com

SOURCE: Current Pharmaceutical Design, (2002) 8/14 (1199-1227).
Refs: 189

ISSN: 1381-6128 CODEN: CPDEFP

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Utilization of fat as a long-term energy storage vehicle is crucial for the maintenance of cellular metabolism and is under intricate and many times redundant control mechanisms. Aberrations in the control of energy metabolism is apparent in diseases such as diabetes and obesity and is evident early on in patients with impaired glucose tolerance. Insulin resistance has been observed at the level of muscle, liver and adipose tissue. Hyperglycemia is the hallmark of diabetes and is characterized by decreased glucose disposal and increased glucose production, driven by enhanced and uncontrolled fatty acid oxidation (FAO). Mechanisms aimed at limiting the availability of substrates or the activity of processes involved in FAO should provide an immediate reduction in undesired glucose production in these individuals. Numerous targets are available which influence directly the metabolism of fat, including limiting availability of substrate to FAO, inhibiting oxidation of the fatty acid per se, and uncoupling the energy obtained during the oxidation of the fatty acid. These include antilipolytic agents which limit the availability of substrate, FAO inhibitors which limit fatty acid transport (carnitine palmitoyl transferase, CoA sequestration), FAO per se (.beta. oxidation), and agents which uncouple the energy of FAO (uncoupling proteins, .beta.3 agonists). These other targets which affect fatty acid metabolism indirectly will be discussed in this review with 184 references.

L70 ANSWER 30 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2002225317 EMBASE

TITLE: [Undesirable effects: Drugs increase the body weight].
UNERWUNSCHTE WIRKUNGEN: ARZNEIMITTEL ERHOEHEN DAS
KORPERGEWICHT.

AUTHOR: Bruhn C.

SOURCE: Deutsche Apotheker Zeitung, (13 Jun 2002) 142/24 (38-41).
ISSN: 0011-9857 CODEN: DAZE2

COUNTRY: Germany

DOCUMENT TYPE: Journal; (Short Survey)

FILE SEGMENT: 030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: German

L70 ANSWER 31 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2003072923 EMBASE

TITLE: Obesity and overweight: Assessment and weight-reduction interventions based on level of risk.

AUTHOR: Lai C.S.

CORPORATE SOURCE: C.S. Lai, Ontario Min. of Hlth./Long Term Care, Toronto, Ont., Canada. claudia.lai@moh.gov.on.ca

SOURCE: Canadian Pharmaceutical Journal, (2002) 185/10 (18-29).

Refs: 64

ISSN: 0828-6914 CODEN: CPJOAC

COUNTRY: Canada

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology

030 Pharmacology

036 Health Policy, Economics and Management

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

L70 ANSWER 32 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2001172502 EMBASE

TITLE: Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: Possible mechanisms of action? [3].

AUTHOR: Dursun S.M.; Devarajan S.

SOURCE: Canadian Journal of Psychiatry, (2001) 46/3 (287-288).

Refs: 5

ISSN: 0706-7437 CODEN: CJPSDF

COUNTRY: Canada

DOCUMENT TYPE: Journal; Letter

FILE SEGMENT: 030 Pharmacology

032 Psychiatry

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

L70 ANSWER 33 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000342225 EMBASE

TITLE: Effects of obesity on pharmacokinetics: Implications for drug therapy.

AUTHOR: Cheymol G.

CORPORATE SOURCE: Prof. G. Cheymol, Department of Pharmacology, Faculty of Medicine Saint-Antoine, 27 rue Chaligny, 75012 Paris, France

SOURCE: Clinical Pharmacokinetics, (2000) 39/3 (215-231).

Refs: 68

ISSN: 0312-5963 CODEN: CPKNDH

COUNTRY: New Zealand

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery

030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Obesity is a worldwide problem, with major health, social and economic implications. The adaptation of drug dosages to obese patients is a subject of concern, particularly for drugs with a narrow therapeutic index. The main factors that affect the tissue distribution of drugs are body composition, regional blood flow and the affinity of the drug for plasma proteins and/or tissue components. Obese people have larger absolute lean body masses as well as fat masses than non-obese individuals of the same age, gender and height. However, the percentage of fat per kg of total bodyweight (TBW) is markedly increased, whereas that of lean

tissue is reduced. Cardiac performance and adipose tissue blood flow may be altered in obesity. There is uncertainty about the binding of drugs to plasma proteins in obese patients. Some data suggest that the activities of hepatic cytochrome P450 isoforms are altered, but no clear overview of drug hepatic metabolism in obesity is currently available. Pharmacokinetic studies provide differing data on renal function in obese patients. This review analyses recent publications on Several Classes of drugs: antibacterials, anticancer drugs, psychotropic drugs, anticonvulsants, general anaesthetics, opioid analgesics, neuromuscular blockers, .beta.-blockers and drugs commonly used in the management of obesity. Pharmacokinetic studies in obesity show that the behaviour of molecules with weak or moderate lipophilicity (e.g. lithium and vecuronium) is generally rather predictable, as these drugs are distributed mainly in lean tissues. The dosage of these drugs should be based on the ideal bodyweight (IBW). However, some of these drugs (e.g. antibacterials and some anticancer drugs) are partly distributed in adipose tissues, and their dosage is based on IBW plus a percentage of the patient's excess bodyweight. There is no systematic relationship between the degree of lipophilicity of markedly lipophilic drugs (e.g. remifentanyl and some .beta.-blockers) and their distribution in Obese individuals. The distribution of a drug between fat and lean tissues may influence its pharmacokinetics in obese patients. Thus, the loading dose should be adjusted to the TBW or IBW, according to data from studies carried out in obese individuals. Adjustment of the maintenance dosage depends on the observed modifications in clearance. Our present knowledge of the influence of obesity on drug pharmacokinetics is limited. Drugs with a small therapeutic index should be used prudently and the dosage adjusted with the help of drug plasma concentrations.

L70 ANSWER 34 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000279357 EMBASE

TITLE: Weight gain and antidepressants.

AUTHOR: Fava M.

CORPORATE SOURCE: Dr. M. Fava, Depression Clinical/Research Program,
Massachusetts General Hospital, ACC 812, 15 Parkman St.,
Boston, MA 02114, United States

SOURCE: Journal of Clinical Psychiatry, (2000) 61/SUPPL. 11
(37-41).

Refs: 44

ISSN: 0160-6689 CODEN: JCLPDE

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Weight gain during antidepressant treatment can be either a sign of improvement in patients who have weight loss as a symptom of depression or a residual symptom in patients who overeat when depressed. However, significant weight gain during the acute phase of treatment or weight gain that continues despite achieving full remission of depressive symptoms is likely to be a side effect of antidepressant treatment. Weight gain is a relatively common problem during both acute and long-term treatment with antidepressants, and it is an important contributing factor to noncompliance. This article will review the literature with regard to the relative risk for weight gain of antidepressants. It appears that tricyclic antidepressants (TCAs) and perhaps monoamine oxidase inhibitors (MAOIs) may be more likely to cause weight gain than the selective serotonin reuptake inhibitors (SSRIs) or the newer antidepressants, with the exception of mirtazapine, which may be placed between the SSRIs and the TCAs in terms of relative risk for weight gain. Paroxetine may be more likely to cause weight gain than the other SSRIs during long-term

treatment, and bupropion and nefazodone may be less likely to cause weight gain than the SSRIs in the long term, although more studies are necessary to confirm these impressions.

L70 ANSWER 35 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000102290 EMBASE

TITLE: Antidepressants to alter brain chemistry.

AUTHOR: Houlton S.

SOURCE: Manufacturing Chemist, (2000) 71/3 (22-23).

Refs: 0

ISSN: 0262-4230 CODEN: MCHMDI

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Note

FILE SEGMENT: 030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The causes of depression are poorly understood, but involve hormones such as serotonin and noradrenaline in the brain, so drug treatments for the disease focus on agonists and reuptake inhibitors for these substances.

L70 ANSWER 36 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 2000104736 EMBASE

TITLE: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines.

AUTHOR: Anderson I.M.; Nutt D.J.; Deakin J.F.W.

CORPORATE SOURCE: I.M. Anderson, University of Manchester, Department of Psychiatry, Stopford Building, Oxford Road, Manchester M13 9PT, United Kingdom. ian.anderson@man.ac.uk

SOURCE: Journal of Psychopharmacology, (2000) 14/1 (3-20).

Refs: 209

ISSN: 0269-8811 CODEN: JOPSEQ

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 030 Pharmacology
032 Psychiatry
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB A revision of the British Association for Psychopharmacology guidelines for treating depressive disorders with antidepressants was undertaken in order to specify the scope and target of the guidelines and to update the recommendations based explicitly on the available evidence. A consensus meeting, involving experts in depressive disorders and their treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is given which identifies the quality of evidence followed by recommendations, the strength of which are based on the level of evidence. The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

L70 ANSWER 37 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 1999263731 EMBASE

TITLE: Maintenance treatment with medroxyprogesterone acetate in

patients with ~~advanced breast cancer~~ responding to chemotherapy: Results of a randomized trial.

AUTHOR: Kloke O.; Klaassen U.; Oberhoff C.; Hartwich G.; Szanto J.; Wolf E.; Heckmann M.; Huhn R.; Stephan L.; Schnepfer U.; Donsbach G.-M.; Bechtel C.; Rudolph R.; Berke A.; Borquez D.; Hawig I.; Hirche H.; Schindler A.E.; Seeber S.; Becher R.

CORPORATE SOURCE: O. Kloke, Dept. Internal Medicine (Canc. Ctr.), West German Cancer Center, University of Essen Medical School, Hufelandstrasse 55, 45122 Essen, Germany

SOURCE: Breast Cancer Research and Treatment, (1999) 55/1 (51-59).
Refs: 22
ISSN: 0167-6806 CODEN: BCTRD6

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The purpose of this randomized phase III trial was to study whether medroxyprogesterone acetate (MPA) maintenance treatment prolongs the time to progression in advanced breast cancer patients responding to an induction chemotherapy. Patients with progressive advanced breast cancer previously untreated with anthracyclines and progestins were given epirubicin (30 mg/m²) and ifosfamide (2 g/m²) on days 1 and 8 at 3-weekly intervals. Patients without disease progression after 6 cycles of chemotherapy were randomly assigned to receive, until progression, either no treatment or MPA at a daily total dose of 500 mg. Ninety patients were randomized: 46 to the MPA arm and 44 to the observation arm. Median time to progression was longer in the MPA arm: 4.9 months versus 3.7 months in the intent-to-treat analysis ($p = 0.02$), and 4.9 months versus 3.0 months in the secondary efficacy analysis ($p = 0.012$). Seven patients were removed from MPA due to side effects. The changes in patient-rated quality of life scores were similar in both groups. The median length of survival from randomization was 17.4 months for patients receiving MPA and 18.3 months for patients randomized to observation ($p = 0.39$). In conclusion, in patients with advanced breast cancer achieving remission or non-progression with 6 cycles of epirubicin and ifosfamide chemotherapy, MPA maintenance treatment led to a significant, though modest, prolongation of the time to progression without affecting overall survival of the study patients.

L70 ANSWER 38 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 1998146142 EMBASE

TITLE: Cardiotoxicity related to cancer therapy.

AUTHOR: ~~Hinkle A.S.; Truesdell S.C.; Proukou C.B.; Constine L.S.~~

CORPORATE SOURCE: A.S. Hinkle, Div. Pediatric Hematology-Oncology, University Rochester Medical Center, Children's Hospital at Strong, Elmwood Avenue, Rochester, NY 14642, United States

SOURCE: Progress in Pediatric Cardiology, (1998) 8/3 (145-155).
Refs: 73
ISSN: 1058-9813 CODEN: PPCAFF

PUBLISHER IDENT.: S 1058-9813(98)00010-1

COUNTRY: Ireland

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 007 Pediatrics and Pediatric Surgery
016 Cancer
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Because of recent advances in treatment of childhood cancer, there are increasing numbers of children who have survived cancer. Their future lives are complicated by late sequelae of the disease and treatment. Cardiovascular late effects are usually correlated with cardiotoxic treatment. Other late effects, however, affect organ systems which may have an impact on a patient's cardiovascular status. Of particular interest are the cardiovascular effects of thyroid dysfunction (either hypothyroidism or hyperthyroidism), growth hormone deficiency, obesity, ovarian failure, pulmonary disease and renal dysfunction. In addition, psychosocial issues, such as risk-taking behavior and neurocognitive abnormalities requiring pharmacotherapy, present further cardiovascular concerns. This review discusses some of the more common non-cardiac sequelae of treatment of childhood cancer which may effect cardiac function. Knowledge of these late effects and their cardiac impact is essential as we attempt to lessen associated morbidity and mortality.

L70 ANSWER 39 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 1998055821 EMBASE

TITLE: Phenelzine use throughout pregnancy and the puerperium: Case report, review of the literature, and management recommendations.

AUTHOR: Gracious B.L.; Wisner K.L.

CORPORATE SOURCE: Dr. B.L. Gracious, Child and Adolescent Mental Health, Scott and White Clinic, 2401 S. 31st Street, Temple, TX 76508, United States

SOURCE: Depression and Anxiety, (1997) 6/3 (124-128). Refs: 26

ISSN: 1091-4269 CODEN: DEANF5

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 010 Obstetrics and Gynecology
024 Anesthesiology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB Little is known about the use of monoamine oxidase inhibitors (MAOIs) during pregnancy and the postpartum period. We present a literature review with what we believe is the second case report of phenelzine exposure throughout pregnancy and the postpartum period. Potential indications for use and principles of the clinical management of the pregnant patient treated with an MAOI are also discussed and include: documenting informed consent, MAOI dose adjusting during pregnancy, monitoring of maternal and fetal outcome, and appropriate analgesia and anesthesia during labor and delivery. Our patient tolerated phenelzine well throughout her pregnancy but experienced recurring depressive symptoms during periods of significant weight gain requiring dose adjustment. Labor, delivery, and the perinatal period progressed without complication for our patient and her infant, in whom no congenital malformation was detected. Additional case reports and animal studies of MAOI use during gestation may help determine safety and refine clinical management guidelines.

L70 ANSWER 40 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 97081205 EMBASE

DOCUMENT NUMBER: 1997081205

TITLE: A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

AUTHOR: Pecknold J.C.

CORPORATE SOURCE: Dr. J.C. Pecknold, Douglas Hospital, 6875 Boul LaSalle, Verdun, Que. H3H 1R3, Canada

SOURCE: Drug Safety, (1997) 16/2 (118-132).

Refs: 241
ISSN: 0114-5916 CODEN: DRSAEA
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Anxiety disorders include generalised anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD) and social phobia. Consideration of the chronicity of these disorders reveals that anxiety disorders first occur during early adolescence or young adulthood, and can wax and wane over periods of 5 to 10 years. Thus, in considering treatment, the emphasis must be placed on long term, rather than short term, management. Comorbidity studies reveal that untreated patients with anxiety disorders are at risk of social and psychological consequences, as well as disability resulting from comorbid and secondary disorders. Comparisons between buspirone and the benzodiazepines in treating patients with generalised anxiety disorder reveal that long term use of benzodiazepines is associated with adverse effects, particularly in elderly patients. Buspirone appears to have an onset of action equivalent to that of the benzodiazepines, to be well tolerated in the long term, to lack problems of habituation and withdrawal, and to be useful in patients with masked comorbid depression. In patients with panic disorder and social phobia, buspirone has not been clearly shown to be effective in comparison with the reference standards; in those patients with OCD, there are only preliminary indications of efficacy, which merit a more adjunctive role.

L70 ANSWER 41 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96314893 EMBASE
DOCUMENT NUMBER: 1996314893
TITLE: [Treatment of depression in the general practice. Part I].
BEHANDLUNG DER DEPRESSIONEN IN DER ALLGEMEINPRAXIS. TEIL I.
AUTHOR: Margraf J.
CORPORATE SOURCE: Klin. Psychol./Psychotherapie, Technische
Universitat,D-01062 Dresden, Germany
SOURCE: Notfall Medizin, (1996) 22/9 (484+486+488-490).
ISSN: 0341-2903 CODEN: NOMEDC
COUNTRY: Germany
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: German

L70 ANSWER 42 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 96135054 EMBASE
DOCUMENT NUMBER: 1996135054
TITLE: Monoamine oxidase inhibitors: An update on drug interactions.
AUTHOR: Livingston M.G.; Livingston H.M.
CORPORATE SOURCE: Univ Department Psychological Med, Academic Centre,
Gartnavel Royal Hospital, 1055 Great Western Road, Glasgow
G12 0XH, United Kingdom
SOURCE: Drug Safety, (1996) 14/4 (219-227).
ISSN: 0114-5916 CODEN: DRSAEA
COUNTRY: New Zealand
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 030 Pharmacology
032 Psychiatry
037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

AB After initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions. Despite their clinical benefits, this has led to a reduction in use of such medications. Discovery of the 2 main subgroups of monoamine oxidase, types A and B, led to the synthesis of MAOIs selective for one or other of these isoenzymes. Consequently, selegiline (deprenyl), a selective MAO-B inhibitor, was developed for the treatment of idiopathic Parkinson's disease. This drug is useful in the treatment of the early stages of the disease and later on as an adjunct to other drug therapies. Although the selective MAO-A inhibitor, clorgiline (clorgyline), was found to be effective in the treatment of depression, it still retained the potential to cause hypertensive reactions. Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy. Whilst they are less likely to induce hypertensive reactions with the concomitant administration of sympathomimetic drugs or with tyramine-rich foodstuffs, it still seems wise to advocate care in co-prescribing potentially interacting medications and to advise a degree of caution with regard to the dietary intake of foodstuffs likely to contain a high tyramine content. Although these newer drugs represent an advance in safety, their use has, as yet, only been established in the treatment of depression. RIMAs also retain a potential for adverse interaction with other drugs. Concomitant prescription of serotonin-enhancing drugs should only be undertaken with caution for patients on moclobemide, toloxatone or selegiline. Coprescription of sympathomimetic drugs should also be avoided with these newer MAOIs and patients should be advised against purchasing over-the-counter preparations that may contain sympathomimetic drugs.

L70 ANSWER 43 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 95080032 EMBASE

DOCUMENT NUMBER: 1995080032

TITLE: [Diagnostic and treatment of panic disorder].
DIAGNOSTICO E TRATAMENTO DO TRANSTORNO DO PANICO.AUTHOR: Versiani M.; Nardi A.E.; Figueira I.; Andrade Y.;
Mendlowicz M.; Marques C.; Coscarelli P.CORPORATE SOURCE: Programa de Ansiedade e Depressao, Universidad Federal, Rio
de Janeiro, BrazilSOURCE: Jornal Brasileiro de Psiquiatria, (1995) 44/2 (99-102).
ISSN: 0047-2085 CODEN: JBPSAX

COUNTRY: Brazil

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 032 Psychiatry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: Portuguese

SUMMARY LANGUAGE: Portuguese; English

AB Panic disorder, pure, is highly treatable, especially, with the drugs: clonazepam, amitriptyline, clomipramine or tranylcypromine. Each of these has a different unwanted effects profile. It is up to the clinician, evaluating each individual case, to choose the best risk-benefit-ratio for the patient. Unwanted effects are preponderant in these decisions: tricyclics (weight gain, cardiotoxicity), tranylcypromine (postural hypertension, hypertensive crises due to interactions), clonazepam (cognitive disturbance, disinhibition). When the panic is not pure, there is comorbidity and the treatment becomes more complex and, also, the preoccupation with unwanted effects augment. Comorbidity results in a more

selective choice of drugs. An antidepressant for panic + depression; a benzodiazepine (clonazepam) to those who do not tolerate 'initial worsening'; tranylcypromine for a very severe and resistant case; and, eventually moclobemide for patients who do not tolerate the unwanted effects of these other medications, because, among other facts, panic patients are symptom free, except during the attacks. When there is a personality disorder prognosis worsens and the treatment becomes more complex.

L70 ANSWER 44 OF 50 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

ACCESSION NUMBER: 94122821 EMBASE
DOCUMENT NUMBER: 1994122821
TITLE: Recent developments in serotonin reuptake inhibitors.
AUTHOR: Shutske G.M.
CORPORATE SOURCE: Neuroscience Strategic Business Unit, Hoechst-Roussel
Pharmaceuticals Inc, Route 202-206, Somerville, NJ
08876-1258, United States
SOURCE: Expert Opinion on Therapeutic Patents, (1994) 4/4
(335-341).
ISSN: 0962-2594 CODEN: EOTPEG
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 008 Neurology and Neurosurgery
030 Pharmacology
032 Psychiatry
037 Drug Literature Index
LANGUAGE: English

L70 ANSWER 45 OF 50 USPATFULL

ACCESSION NUMBER: 2002:55034 USPATFULL
TITLE: Methods and compositions for using moclobemide
INVENTOR(S): Klein, Donald F., New York, NY, UNITED STATES
Lederman, Seth, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032197	A1	20020314
APPLICATION INFO.:	US 20010772679	A1	20010130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US17274, filed on 31 Jul 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94934P	19980731 (60)
	US 1998-94984P	19980731 (60)
	US 1998-94985P	19980731 (60)
	US 1998-94987P	19980731 (60)
	US 1998-94989P	19980731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1941	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods and compositions for treating, managing, and/or preventing certain pain and pain disorder, ~~posttraumatic stress disorder (PTSD)~~, premenstrual dysphoric disorder and premenstrual syndrome, certain sleep disorders, eating disorders, and symptoms thereof using moclobemide, a moclobemide metabolite, a moclobemide derivative or a moclobemide composition.

IT 64544-22-5, Moclobemide hydrochloride 71320-77-9,

Moclobemide 71320-77-9D, Moclobemide, derivs. or metabolites
(comps. contg. moclobemide for treatment of pain)

L70 ANSWER 46 OF 50 USPATFULL

ACCESSION NUMBER: 1999:128762 USPATFULL

TITLE: Oxazolidin-2-one derivatives, preparation method
therefor and ~~therapeutic use~~ thereof

INVENTOR(S): Jegham, Samir, Argenteuil, France
Puech, Frederic, Rueil Malmaison, France
Burnier, Philippe, Maisons Laffitte, France
Berthon, Danielle, Mareil Marly, France
Leclerc, Odile, Rueil Malmaison, France

PATENT ASSIGNEE(S): Synthelabo, Le Plessis Robinson, France (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5969146		19991019
	WO 9713768		19970417
APPLICATION INFO.:	US 1998-51539		19980413 (9)
	WO 1996-FR1511		19961008
			19980413 PCT 371 date
			19980413 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1995-11902	19951011
	FR 1996-9361	19960725
	FR 1996-9362	19960725

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Jacobson, Price, Holman & Stern, PLLC
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 1333

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds derived from oxazolidin-2-one of formula (I) ##STR1## in
which: R.sub.1 represents a hydrogen atom, an alkyl group, a
hydroxyalkyl group, a fluoroalkyl group, a hydroxyfluoroalkyl group, a
cyanoalkyl group, a substituted or unsubstituted phenyl group, a
substituted or unsubstituted phenylmethyl group or an R.sub.3 A- group
in which R.sub.3 is a cycloalkyl or cyclooxyalkyl group which is
unsubstituted or substituted by a hydroxyl group and A is a --CH.sub.2
or --CH.sub.2 --CH.sub.2 radical,

R.sub.2 represents a hydrogen atom or a methyl group,

X represents an oxygen or sulphur atom or an NR.sub.4 group where
R.sub.4 is an alkyl group or a hydrogen atom, and

Z represents an oxygen atom or a --CH.dbd.CH or --CH.sub.2 --CH.sub.2
group,

their process of preparation and their applications in therapeutics.

IT 189439-39-2P 189439-83-6P

(prepn. of oxazolidinone derivs. as monoamine oxidase inhibitors)

L70 ANSWER 47 OF 50 USPATFULL

ACCESSION NUMBER: 1999:89641 USPATFULL

TITLE: Universal solenoid actuator

INVENTOR(S): Frolov, George, Farmington, CT, United States

PATENT ASSIGNEE(S): Harrow Products, Inc., Grand Rapids, MI, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5933067		19990803
APPLICATION INFO.:	US 1998-93013		19980605 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-49254P	19970610 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gellner, Michael L.	
ASSISTANT EXAMINER:	Nguyen, Tuyen T.	
LEGAL REPRESENTATIVE:	Alix, Yale & Ristas, LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	396	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A universal solenoid actuator for use with either a fail-safe or a fail-secure lock mechanism or a push-type or pull-type mechanism comprises a reversible coil assembly, at least one plunger and a module for receiving electricity from a power supply and delivering the electricity to the coil assembly. The coil assembly includes a housing which defines a bore extending through the coil assembly, at least one coil surrounding the bore and first and second fittings at opposed ends of the bore. The plunger is received within the bore and is actuated upon application of an electrical potential to the coil assembly. When used with a fail-safe lock, the first fitting is affixed to the lock. When used with a fail-secure lock, the coil assembly is reversed to affix the second fitting to the lock. Variations of the preferred embodiment of the inventive universal solenoid actuator are disclosed.

IT 63638-91-5, Brofaromine 71320-77-9, Moclobemide
(serotonergic drug for treatment of stress)

L70 ANSWER 48 OF 50 USPATFULL

ACCESSION NUMBER: 97:54235 USPATFULL

TITLE: Oxazoloquinolinone derivatives, their preparation and their therapeutic application as inhibitors of monoamine oxidase

INVENTOR(S): Jegham, Samir, Argenteuil, France
Koenig, Jean Jacques, Maisons Laffitte, France
Puech, Frederic, Rueil Malmaison, France
Burnier, Philippe, Maisons Laffitte, France
Zard, Lydia, Gif sur Yvette, France

PATENT ASSIGNEE(S): Synthelabo, Le Plessis Robinson, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5641785		19970624
APPLICATION INFO.:	US 1995-523508		19950901 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-10600	19940905
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Huang, Evelyn	
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC	
NUMBER OF CLAIMS:	8	

EXEMPLARY CLAIM: 1
LINE COUNT: 1341

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 3,3a,4,5-Tetrahydro-1H-oxazolo[3,4-a]quinolin-1-one derivatives of
formula (I) ##STR1## in which: n is 0 or 1,

R.sub.1 represents a hydrogen atom or an ethenyl, methyl, ethyl, phenyl,
hydroxymethyl or methoxymethyl group, and

(i) R.sub.2 is a methyl, trifluoromethyl or cyano group, R.sub.3 is a
hydrogen atom or a hydroxyl or benzyloxy group and R.sub.4 and R.sub.5
are hydrogen atoms,

or (ii) R.sub.2 and R.sub.4 together form a --(CH.sub.2).sub.4 -- group,
R.sub.3 is a hydroxyl group and R.sub.5 is a hydrogen atom,

or (iii) R.sub.2 and R.sub.5 together form an --O--(CH.sub.2).sub.3 --
group, and R.sub.3 and R.sub.4 are hydrogen atoms,

or (iv) R.sub.2 and R.sub.5 together form a --(CH.sub.2).sub.4 group,
R.sub.3 is a hydroxyl group and R.sub.4 is a hydrogen atom,

are useful as selective inhibitors of MAO-A or as mixed inhibitors of
MAO-A and MAO-B.

IT 176773-86-7P

(prepn. of oxazoloquinolinones as monoamine oxidase inhibitors)

L70 ANSWER 49 OF 50 USPATFULL

ACCESSION NUMBER: 93:3607 USPATFULL

TITLE: Compositions for treating tobacco withdrawal sytoms and
methods for their use

INVENTOR(S): Wurtman, Richard J., Boston, MA, United States
Wurtman, Judith J., Boston, MA, United States
Spring, Bonnie, Chicago, IL, United States

PATENT ASSIGNEE(S): Massachusettes Institute of Technology, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5179126		19930112
APPLICATION INFO.:	US 1990-619301		19901128 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-262625, filed on 26. Oct 1988, now patented, Pat. No. US 4999382		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Friedman, B. J.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	427		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions useful in the treatment of disturbances of appetite,
disturbances of mood, or both, nicotine withdrawal associated as well as
experienced by individuals after discontinuing tobacco use as methods of
use therefor. The compositions include serotoninerbic drugs, such as
d-fenfluramine and fluoxetine.

IT 63638-91-5 71320-77-9, Moclobemide
(tobacco withdrawal symptoms treatment with)

L70 ANSWER 50 OF 50 USPATFULL

ACCESSION NUMBER: 91:20696 USPATFULL

TITLE: Compositions for treating tobacco withdrawal symptoms
and methods for their use

INVENTOR(S): Wurtman, Richard J., Boston, MA, United States

PATENT ASSIGNEE(S):

Wurtman, Judith J., Boston, MA, United States
 Spring, Bonnie, Chicago, IL, United States
 Massachusetts Institute of Technology, Cambridge, MA,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4999382		19910312
APPLICATION INFO.:	US 1988-262625		19881026 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Friedman, Stanley J.		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	439		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, nicotine withdrawal associated as well as experienced by individuals after discontinuing tobacco use as methods of use therefor. The compositions include serotonergic drugs, such as d-fenfluramine and fluoxetine.

IT 63638-91-5 71320-77-9, Moclobemide
 (tobacco withdrawal symptoms treatment with)

FILE 'HOME' ENTERED AT 12:41:52 ON 09 MAY 2003

EP 699,680 → 5641,785 + method treating obesity
 WO 96/38444 → 5,843,975 ↓ body weight
 WO 97/13768 → 5,969,116 bulimia associated w/ marked alteration in
 monoaminergic systems
 EP 424,244 ✓ → many MAOI → bulimia nervosa
 US 3,466,236 reversible + irreversible
 3,153,092 brofaromine - selective reversible MAOI

5,574,085 5,235,063

5,173,490

5,036,010

5,171,747

5,196,543

5,182,296

5,332,754